Joel Ackerman, CFO and Treasurer, has demonstrated a clear selling bias in his recent insider transactions, primarily involving DaVita Inc. (DVA) and a smaller position in Champions Oncology, Inc. (CSBR). Since 2024, Ackerman has executed $24.18 million in total sales against $11.15 million in purchases, with the most significant activity concentrated in DVA. His largest dispositions occurred on March 15, 2026, when he sold $5.08 million and $868,900 worth of DVA shares, following earlier sales of $5.07 million and $506,720 the same day. These transactions were preceded by a February 2026 sale of $4.8 million worth of DVA shares, classified as a derivative transaction (Code D), alongside an option exercise (Code M) of equal value.
Ackerman’s trading in DVA follows a recurring pattern around mid-March, with notable sales in 2024 ($2.31 million) and 2025 ($477,831 and $443,690). His only recent purchases were in CSBR, acquiring $144,268 in November 2025 and $198,250 in October 2025, though these were minor compared to his DVA disposals. The absence of recent buys in DVA suggests a sustained reduction in his position, with the bulk of his sales occurring in early 2026. While some transactions involved derivative adjustments (Code A with $0 value), the overall trend points to a deliberate unwinding of his DVA holdings rather than routine portfolio rebalancing.
AI-assisted summary